Sadaf Rabiah, Ali Faiza Sadaqat, Rasheed Tazeen, Zuberi Bader Faiyaz
Rabiah Sadaf, FCPS., Consultant Physician, Dr Ruth K.M. Pfau, Civil Hospital Karachi, Pakistan.
Faiza Sadaqat Ali, FCPS., Senior Registrar, Department of Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
Pak J Med Sci. 2023 Mar-Apr;39(2):430-433. doi: 10.12669/pjms.39.2.6236.
To determine the effect of Remdesivir on liver enzymes and renal functions in SARS-CoV-2 patients.
This prospective cohort study was conducted at Dr. Ruth KM Pfau, Civil Hospital Karachi between 1 December 2021 to 31 January, 2022. All patients of severe SARS-CoV-2 infection who received Inj. Remdesivir for five days as per protocol of SARS-CoV-2 management were included. Biodata of selected patients including age, gender, diabetic, hypertensive status was recorded. Patients Liver Function Tests and Serum Creatinine were performed on days 0, 3, 5, 7 and 14.
This study included 85 patients, out of which 55 (64.7%) were males and 30 (35.3%) were females. Out of 85 patients, Remdesivir was stopped in 3 (3.5%) patients. Among these three patients Remdesivir was stopped in one patient on day three because of decrease in CrCl to <30 ml/min. His CrCl improved after stopping Remdesivir. In the remaining two patients, Remdesivir was stopped due to increase in ALT to greater than 10 times from normal values on day three. Similarly, in these two patients the ALT improved after stopping Remdesivir.
Only three patients developed adverse effects resulting in stopping of Remdesivir, however these were reversible on stopping the drug. Therefore, Remdesivir is a relatively safe drug and well tolerated in SARS-CoV-2 patients.
确定瑞德西韦对新型冠状病毒肺炎（SARS-CoV-2）患者肝酶和肾功能的影响。
这项前瞻性队列研究于2021年12月1日至2022年1月31日在卡拉奇市民医院鲁思·KM·普法博士医院进行。纳入所有按照SARS-CoV-2管理方案接受5天注射用瑞德西韦治疗的重症SARS-CoV-2感染患者。记录入选患者的生物数据，包括年龄、性别、糖尿病、高血压状况。在第0、3、5、7和14天对患者进行肝功能检查和血清肌酐检测。
本研究纳入85例患者，其中55例（64.7%）为男性，30例（35.3%）为女性。85例患者中，3例（3.5%）停用了瑞德西韦。在这3例患者中，1例患者在第3天因肌酐清除率（CrCl）降至<30 ml/min而停用瑞德西韦。停用瑞德西韦后其CrCl有所改善。在其余2例患者中，因第3天谷丙转氨酶（ALT）升高至正常值的10倍以上而停用瑞德西韦。同样，这2例患者停用瑞德西韦后ALT有所改善。
只有3例患者出现不良反应导致停用瑞德西韦，但停药后这些反应是可逆的。因此，瑞德西韦是一种相对安全的药物，在SARS-CoV-2患者中耐受性良好。
